Literature DB >> 18052078

Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.

Eva Papp1, Joyce K Y Tse, Hoangdung Ho, Sandra Wang, David Shaw, Simon Lee, Jim Barnett, David C Swinney, J Michael Bradshaw.   

Abstract

Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase that plays an important signaling role in several types of immune cells. To improve our understanding of the enzymology and activation mechanism of Syk, we characterized the steady state kinetics of Syk substrate phosphorylation. A new real time fluorescence kinase assay was employed that utilizes a nonnatural amino acid in the peptide substrate which undergoes an enhancement in fluorescence following phosphorylation. Characterizing the steady state kinetics using a Syk kinase domain construct [Syk(360-635)] revealed that Syk employs a ternary complex kinetic mechanism involving little cooperativity between substrate binding sites and a Km(ATP) of 36 +/- 5 microM and a Km(peptide substrate) of 4.4 +/- 0.9 microM. The order of substrate binding was determined to be either random or ordered with ATP binding first, as determined in substrate analogue inhibitor studies. Utilizing the real time capabilities of the fluorescence assay, we established that Syk demonstrates no lag phase in product formation. Furthermore, a Syk mutant lacking tyrosine in the activation loop (Syk Y525F,Y526F) exhibited activity identical to that of wild-type Syk. These two findings indicate that autophosphorylation of the activation loop of Syk does not regulate Syk(360-635) activity. We also compared the activity of Syk(360-635) to that of full-length Syk and revealed that Syk(360-635) is 10-fold more active, suggesting that residues outside the catalytic domain of Syk suppress kinase activity. The findings presented here provide the first kinetic description of the Syk enzyme mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052078     DOI: 10.1021/bi701596u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Online electrospray ionization mass spectrometric monitoring of protease-catalyzed reactions in real time.

Authors:  Zhan Yu; Lee Chuin Chen; Mridul Kanti Mandal; Hiroshi Nonami; Rosa Erra-Balsells; Kenzo Hiraoka
Journal:  J Am Soc Mass Spectrom       Date:  2012-04       Impact factor: 3.109

2.  A reevaluation of the spleen tyrosine kinase (SYK) activation mechanism.

Authors:  My S Mansueto; Abigail Reens; Larissa Rakhilina; An Chi; Bo-Sheng Pan; J Richard Miller
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

3.  Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.

Authors:  Justin Hall; Ann Aulabaugh; Francis Rajamohan; Shenping Liu; Neelu Kaila; Zhao-Kui Wan; Mark Ryan; Rachelle Magyar; Xiayang Qiu
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

4.  Phosphorylated immunoreceptor tyrosine-based activation motifs and integrin cytoplasmic domains activate spleen tyrosine kinase via distinct mechanisms.

Authors:  Lina Antenucci; Vesa P Hytönen; Jari Ylänne
Journal:  J Biol Chem       Date:  2018-02-12       Impact factor: 5.157

5.  Regulation of Syk by phosphorylation on serine in the linker insert.

Authors:  Leela L Paris; Jianjie Hu; Jacob Galan; Su Sien Ong; Victoria A Martin; Haiyan Ma; W Andy Tao; Marietta L Harrison; Robert L Geahlen
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

6.  A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition.

Authors:  Andrew M Lipchik; Renee L Killins; Robert L Geahlen; Laurie L Parker
Journal:  Biochemistry       Date:  2012-09-12       Impact factor: 3.162

Review 7.  Syk and pTyr'd: Signaling through the B cell antigen receptor.

Authors:  Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2009-03-21

8.  Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.

Authors:  Cheng Liao; Jonathan Hsu; Yong Kim; Dong-Qing Hu; Daigen Xu; Jun Zhang; Achal Pashine; John Menke; Toni Whittard; Natasha Romero; Theresa Truitt; Michelle Slade; Christine Lukacs; Johannes Hermann; Mingyan Zhou; Matthew Lucas; Satwant Narula; Julie DeMartino; Seng-Lai Tan
Journal:  Arthritis Res Ther       Date:  2013-10-04       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.